| 73.23 -14.46 (-16.49%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 102.42 |
1-year : | 114.43 |
| Resists | First : | 87.69 |
Second : | 97.97 |
| Pivot price | 91.13 |
|||
| Supports | First : | 71.06 |
Second : | 59.12 |
| MAs | MA(5) : | 85.68 |
MA(20) : | 90.86 |
| MA(100) : | 81.77  |
MA(250) : | 87.77 |
|
| MACD | MACD : | -0.7 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 21.7 |
| RSI | RSI(14): 28 |
|||
| 52-week | High : | 130.21 | Low : | 55.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MLAB ] has closed below the lower bollinger band by 30.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MLAB ] is to continue within current trading range. It is unclear right now based on current values. 80% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 86.11 - 86.53 | 86.53 - 86.94 |
| Low: | 70.02 - 70.47 | 70.47 - 70.9 |
| Close: | 72.39 - 73.11 | 73.11 - 73.82 |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Tue, 10 Mar 2026
Capone Mark Christopher buys Mesa Laboratories shares for $99,331 - Investing.com
Tue, 10 Mar 2026
Insider Buying: Mesa Laboratories (NASDAQ:MLAB) Director Buys 3,500 Shares of Stock - MarketBeat
Tue, 10 Mar 2026
Insider Buying: Mark Capone Acquires Shares of Mesa Laboratories Inc (MLAB) - GuruFocus
Tue, 10 Mar 2026
Insider Buying: R Tripeny Acquires Shares of Mesa Laboratories I - GuruFocus
Tue, 10 Mar 2026
Mesa Laboratories: Hard To Set The Right Diagnosis (NASDAQ:MLAB) - Seeking Alpha
Tue, 10 Mar 2026
Tripeny R Tony, director, buys $99k in Mesa Laboratories (MLAB) - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Hardware, Equipment & Parts
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 92 (%) |
| Shares Short | 212 (K) |
| Shares Short P.Month | 247 (K) |
| EPS | 0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.79 |
| Profit Margin | 1.5 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 2.1 % |
| Qtrly Rev. Growth | 3.5 % |
| Gross Profit (p.s.) | 27.98 |
| Sales Per Share | 44.84 |
| EBITDA (p.s.) | 7.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 42 (M) |
| Levered Free Cash Flow | 37 (M) |
| PE Ratio | 112.66 |
| PEG Ratio | 0 |
| Price to Book value | 2.16 |
| Price to Sales | 1.63 |
| Price to Cash Flow | 9.73 |
| Dividend | 0.15 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|